These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23934763)

  • 1. Kinase inhibitor therapy in CML: it's what's inside that counts.
    Eide CA; Druker BJ; O'Hare T
    Oncotarget; 2013 Sep; 4(9):1332-3. PubMed ID: 23934763
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of the new patient with CML in chronic phase.
    Marin D
    Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
    Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
    Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line therapy for CML: nilotinib comes of age.
    Davies J
    Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
    [No Abstract]   [Full Text] [Related]  

  • 7. Remission status should not be treated as a base-line covariate--reply to Etienne et al.
    Lauseker M; Hasford J
    Haematologica; 2014 Sep; 99(9):e174-5. PubMed ID: 25176984
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib in chronic myeloid leukemia elderly patients.
    Gugliotta G; Castagnetti F; Palandri F; Baccarani M; Rosti G
    Aging (Albany NY); 2011 Dec; 3(12):1125-6. PubMed ID: 22203437
    [No Abstract]   [Full Text] [Related]  

  • 9. Bosutinib in the treatment of chronic myelogenous leukemia.
    Cortes J
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
    [No Abstract]   [Full Text] [Related]  

  • 10. 3. Imatinib therapy in chronic myelogenous leukemia.
    Jinnai I
    Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
    [No Abstract]   [Full Text] [Related]  

  • 11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.
    Westin JR; Kurzrock R
    Mol Cancer Ther; 2012 Dec; 11(12):2549-55. PubMed ID: 23204432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
    Press RD
    Oncologist; 2010; 15(7):744-9. PubMed ID: 20566700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
    Baccarani M
    Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
    Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
    Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular response in CML: where is the bar?
    Baccarani M; Soverini S
    Blood; 2014 Jul; 124(4):469-71. PubMed ID: 25061165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
    Wolf D
    Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
    [No Abstract]   [Full Text] [Related]  

  • 18. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing tolerability of TKI therapy in CML.
    Hochhaus A
    Blood; 2014 Feb; 123(9):1284-5. PubMed ID: 24578491
    [No Abstract]   [Full Text] [Related]  

  • 20. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
    Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
    Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.